Christopher M. Florkowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christopher M. Florkowski has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Bobby Li
Te Whatu Ora – Health New Zealand Waitaha Canterbury, Christchurch, New Zealand
2 shared publications Peter M George
Biochemistry Department, Canterbury Health Laboratories, Christchurch, New Zealand
2 shared publicationsPeter M. George
Canterbury Health Laboratories, Christchurch, New Zealand
2 shared publications- Sarah L. Molyneux
Canterbury Health Laboratories, Christchurch, New Zealand
2 shared publications A Mark Richards
1 shared publication- Alexa Kidd
Genetics Department Canterbury Health laboratory Christchurch New Zealand
1 shared publication
Latest Publications
- Open Access
- 28 August 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (2) , 433-439
Analytical verification of the Atellica VTLi point of care high sensitivity troponin I assay
Objectives: The Siemens Point-of-Care Testing (POC) Atellica® VTLi high-sensitivity troponin I (hsTnI) device has been previously validated. Verification independently provides evidence that an analytical procedure fulfils concordance with laboratory assays, imprecision, and hemolysis interference requirements. Methods: Five whole blood samples spanning the measuring interval were analysed 20 times in succession. Hemolysis interference was assessed at three troponin concentrations by spiking five hemolysate concentrations to plasma to achieve free hemoglobin concentrations 35–1,000 mg/dL. Concordance between whole blood (VTLi) and plasma on laboratory analysers (Beckman, Roche, Siemens) was assessed by Pearson correlation and kappa statistics at the (LOQ) and upper reference limit (URL). This was repeated for frozen plasma samples. Results: Coefficients of variation for whole blood were <10 % for whole blood troponin concentrations of 9.2 and 15.9 ng/L, thus below the URL. Hemolysis positively interfered; at 250 mg/dL affecting the low troponin sample (+3 ng/L; +60 %) and high troponin sample (+37 ng/L; +24 %). Correlation coefficients were 0.98, 0.90 and 0.97 between VTLi and Beckman, Roche and Siemens assays respectively. Corresponding kappa statistics were 0.80, 0.73 and 0.84 at the LOQ and 0.70, 0.44 and 0.67 at the URL. Conclusions: Concordances between VTLi and laboratory assays were at least non-inferior to those between laboratory assays. Imprecision met manufacturer claims and was consistent with a high sensitivity assay. There is potential for hemolysis interference, highlighting the need for quality samples. The results support performance characteristics previously reported in validation studies, and the device offers acceptable performance for use within intended medical settings.
- 28 August 2024
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 63 (2) , 433-439
Open AccessAnalytical verification of the Atellica VTLi point of care high sensitivity troponin I assay
Objectives: The Siemens Point-of-Care Testing (POC) Atellica® VTLi high-sensitivity troponin I (hsTnI) device has been previously validated. Verification independently provides evidence that an analytical procedure fulfils concordance with laboratory assays, imprecision, and hemolysis interference requirements. Methods: Five whole blood samples spanning the measuring interval were analysed 20 times in succession. Hemolysis interference was assessed at three troponin concentrations by spiking five hemolysate concentrations to plasma to achieve free hemoglobin concentrations 35–1,000 mg/dL. Concordance between whole blood (VTLi) and plasma on laboratory analysers (Beckman, Roche, Siemens) was assessed by Pearson correlation and kappa statistics at the (LOQ) and upper reference limit (URL). This was repeated for frozen plasma samples. Results: Coefficients of variation for whole blood were <10 % for whole blood troponin concentrations of 9.2 and 15.9 ng/L, thus below the URL. Hemolysis positively interfered; at 250 mg/dL affecting the low troponin sample (+3 ng/L; +60 %) and high troponin sample (+37 ng/L; +24 %). Correlation coefficients were 0.98, 0.90 and 0.97 between VTLi and Beckman, Roche and Siemens assays respectively. Corresponding kappa statistics were 0.80, 0.73 and 0.84 at the LOQ and 0.70, 0.44 and 0.67 at the URL. Conclusions: Concordances between VTLi and laboratory assays were at least non-inferior to those between laboratory assays. Imprecision met manufacturer claims and was consistent with a high sensitivity assay. There is potential for hemolysis interference, highlighting the need for quality samples. The results support performance characteristics previously reported in validation studies, and the device offers acceptable performance for use within intended medical settings.
- Open Access
- 18 March 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (5) , 706-707
Commentary on Glycerol Kinase Deficiency with Increased Triglycerides and Weight Gain: Pseudo or Real?
The authors present the case of a 20-year-old male with elevated triglycerides, although with clear plasma and non-elevated lipemic index. Having identified this inconsistency, suspicion of glycerol kinase deficiency (GKD) was confirmed by demonstration of elevated plasma glycerol and the finding of a mutation in the glycerol kinase gene on chromosome Xp21. This constellation of elevated triglycerides with clear plasma and non-elevated lipemic index is important to recognize in order that elevated cardiovascular risk is not inappropriately assigned and to prevent exposure of patients to unnecessary lipid-modifying drugs. This presents an opportunity where clinical laboratories can be proactive in identifying an inconsistency between lipemic index and measured triglycerides, raising the awareness of GKD amongst clinicians and suggesting appropriate further investigations.
- 18 March 2024
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 70 (5) , 706-707
Open AccessCommentary on Glycerol Kinase Deficiency with Increased Triglycerides and Weight Gain: Pseudo or Real?
The authors present the case of a 20-year-old male with elevated triglycerides, although with clear plasma and non-elevated lipemic index. Having identified this inconsistency, suspicion of glycerol kinase deficiency (GKD) was confirmed by demonstration of elevated plasma glycerol and the finding of a mutation in the glycerol kinase gene on chromosome Xp21. This constellation of elevated triglycerides with clear plasma and non-elevated lipemic index is important to recognize in order that elevated cardiovascular risk is not inappropriately assigned and to prevent exposure of patients to unnecessary lipid-modifying drugs. This presents an opportunity where clinical laboratories can be proactive in identifying an inconsistency between lipemic index and measured triglycerides, raising the awareness of GKD amongst clinicians and suggesting appropriate further investigations.
- Open Access
- 3 April 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (4) , 334
Commentary on Persistent Hypercalcemia: Choose Your Testing Strategy Carefully
The authors present the case of a 50-year-old male with intermittent, apparently asymptomatic hypercalcemia, nonsuppressed parathyroid hormone, and low-normal urine calcium. Urine calcium to creatinine clearance ratio was supportive of familial hypocalciuric hypercalcemia (FHH), also consistent with his family history of mild hypercalcemia. Although initial CASR sequencing failed to reveal any pathogenic variants, subsequent, more detailed genetic analysis found a heterozygous deletion of CASR exons 5–7, a pathogenic FHH type 1 variant.
- 3 April 2023
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 69 (4) , 334
Open AccessCommentary on Persistent Hypercalcemia: Choose Your Testing Strategy Carefully
The authors present the case of a 50-year-old male with intermittent, apparently asymptomatic hypercalcemia, nonsuppressed parathyroid hormone, and low-normal urine calcium. Urine calcium to creatinine clearance ratio was supportive of familial hypocalciuric hypercalcemia (FHH), also consistent with his family history of mild hypercalcemia. Although initial CASR sequencing failed to reveal any pathogenic variants, subsequent, more detailed genetic analysis found a heterozygous deletion of CASR exons 5–7, a pathogenic FHH type 1 variant.
- 14 May 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 107, 62-66
Hb Westport [β121 (GH4) Glu>Asp; HBB:c.366A>C]: A novel β-globin variant interfering with HbA1c measurement
- 14 May 2022
- Published by Elsevier in Clinical Biochemistry
- Vol. 107, 62-66
Hb Westport [β121 (GH4) Glu>Asp; HBB:c.366A>C]: A novel β-globin variant interfering with HbA1c measurement
- 4 June 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (10) , 2941-2950
Expanding the clinical and radiological phenotypes of leukoencephalopathy due to biallelic HMBS mutations
Pathogenic heterozygous variants in HMBS encoding the enzyme hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase, cause acute intermittent porphyria (AIP). Biallelic variants in HMBS have been reported in a small number of children with severe progressive neurological disease and in three adult siblings with a more slowly, progressive neurological disease and distinct leukoencephalopathy. We report three further adult individuals who share a distinct pattern of white matter abnormality on brain MRI in association with biallelic variants in HMBS , two individuals with homozygous variants, and one with compound‐heterozygous variants. We present their clinical and radiological features and compare these with the three adult siblings previously described with leukoencephalopathy and biallelic HMBS variants. All six affected individuals presented with slowly progressive spasticity, ataxia, peripheral neuropathy, with or without mild cognitive impairment, and/or ocular disease with onset in childhood or adolescence. Their brain MRIs show mainly confluent signal abnormalities in the periventricular and deep white matter and bilateral thalami. This recognizable pattern of MRI abnormalities is seen in all six adults described here. Biallelic variants in HMBS cause a phenotype that is distinct from AIP. It is not known whether AIP treatments benefit individuals with HMBS ‐related leukoencephalopathy. One individual reported here had improved neurological function for 12 months following liver transplantation followed by decline and progression of disease.
- 4 June 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (10) , 2941-2950
Expanding the clinical and radiological phenotypes of leukoencephalopathy due to biallelic HMBS mutations
Pathogenic heterozygous variants in HMBS encoding the enzyme hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase, cause acute intermittent porphyria (AIP). Biallelic variants in HMBS have been reported in a small number of children with severe progressive neurological disease and in three adult siblings with a more slowly, progressive neurological disease and distinct leukoencephalopathy. We report three further adult individuals who share a distinct pattern of white matter abnormality on brain MRI in association with biallelic variants in HMBS , two individuals with homozygous variants, and one with compound‐heterozygous variants. We present their clinical and radiological features and compare these with the three adult siblings previously described with leukoencephalopathy and biallelic HMBS variants. All six affected individuals presented with slowly progressive spasticity, ataxia, peripheral neuropathy, with or without mild cognitive impairment, and/or ocular disease with onset in childhood or adolescence. Their brain MRIs show mainly confluent signal abnormalities in the periventricular and deep white matter and bilateral thalami. This recognizable pattern of MRI abnormalities is seen in all six adults described here. Biallelic variants in HMBS cause a phenotype that is distinct from AIP. It is not known whether AIP treatments benefit individuals with HMBS ‐related leukoencephalopathy. One individual reported here had improved neurological function for 12 months following liver transplantation followed by decline and progression of disease.
- 27 July 2018
- Vol. 131 (1479) , 86-87
Topiramate induced renal tubular acidosis
- 1 August 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 142, 125-135
Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma
- 1 August 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 142, 125-135
Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma
- 1 March 2017
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 1 (5) , 592-594
Will the Use of Lyophilized Citrate Tubes Lead to the Over-Diagnosis of Diabetes in Pregnancy?
- 1 March 2017
- Published by Oxford University Press (OUP) in The Journal of Applied Laboratory Medicine
- Vol. 1 (5) , 592-594
Will the Use of Lyophilized Citrate Tubes Lead to the Over-Diagnosis of Diabetes in Pregnancy?
- 1 January 2017
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 55 (4) , e77-e79
Deciphering a macro-troponin I complex; a case report
- 1 January 2017
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 55 (4) , e77-e79
Deciphering a macro-troponin I complex; a case report
- Open Access
- 1 September 2016
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 62 (9) , 1184-1185
Commentary
This case study considers the diagnostic dilemma of an acute neurological deterioration in a patient with chronic HIV infection, following the commencement of HAART. Although acute porphyria is part of the differential diagnosis, it was not considered until relatively late, which is often the case in other scenarios and reflects the rarity of acute porphyria and the relative lack of familiarity of many clinicians with these disorders. The seminal observation was that of …
- 1 September 2016
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 62 (9) , 1184-1185
Open AccessCommentary
This case study considers the diagnostic dilemma of an acute neurological deterioration in a patient with chronic HIV infection, following the commencement of HAART. Although acute porphyria is part of the differential diagnosis, it was not considered until relatively late, which is often the case in other scenarios and reflects the rarity of acute porphyria and the relative lack of familiarity of many clinicians with these disorders. The seminal observation was that of …